Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Felizzi · SciRah

Researcher profile · Semantic Scholar

F. Felizzi

Share profile

F. Felizzi — researcher profile on SciRah

h-index: 10
Works: 59
Citations: 670

Most-cited papers

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer
L. Fehrenbacher, J. von Pawel, Keunchil Park, A. Rittmeyer +19 more
2018Journal of Thoracic Oncology227 citations Open access
Semantic Scholar
Excitotoxicity Downregulates TrkB.FL Signaling and Upregulates the Neuroprotective Truncated TrkB Receptors in Cultured Hippocampal and Striatal Neurons
J. R. Gomes, J. T. Costa, Carlos V. Melo, F. Felizzi +7 more
2012Journal of Neuroscience99 citations Open access
Semantic Scholar
Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force.
W. Padula, N. Kreif, D. Vanness, B. Adamson +6 more
2022Value in Health77 citations Open access
Semantic Scholar
Patient‐Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small‐cell Lung Cancer
R. Bordoni, F. Ciardiello, J. von Pawel, D. Cortinovis +8 more
2018Clinical Lung Cancer69 citations Open access
Semantic Scholar
Mixture Cure Models in Oncology: A Tutorial and Practical Guidance
F. Felizzi, N. Paracha, J. Pöhlmann, J. Ray
2021PharmacoEconomics - Open51 citations Open access
Semantic Scholar
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
U. Ondhia, H. Conter, S. Owen, Anna Zhou +7 more
2019Journal of Medical Economics26 citations Open access
Semantic Scholar
Analyzing and constraining signaling networks: parameter estimation for the user.
Florian Geier, Georgios Fengos, F. Felizzi, D. Iber
2012Methods in molecular biology21 citations
Semantic Scholar
A Social Media Listening Study to Understand the Unmet Needs and Quality of Life in Adult and Pediatric Amblyopia Patients
A. Syntosi, F. Felizzi, C. Bouchet
2022Ophthalmology and Therapy20 citations Open access
Semantic Scholar
Qualitative Exploration of the Visual Function Impairments and Health-Related Quality of Life Impacts of Amblyopia in Adult and Pediatric Populations
S. Randhawa, Natasha Griffiths, Paul O’Brien, Charlotte Panter +6 more
2023Ophthalmology and Therapy18 citations Open access
Semantic Scholar
Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
Sivignon Marine, Roze Stéphane, Plommet Nicolas, F. Felizzi +3 more
2020Journal of Medical Economics17 citations Open access
Semantic Scholar
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
K. Betts, P. Thuresson, F. Felizzi, E. Du +4 more
2020Journal of Comparative Effectiveness Research9 citations Open access
Semantic Scholar
Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
Shelby Sydnor, Swarnendu Chatterjee, P. Cooney, S. Kaur +6 more
2023Diabetes Therapy6 citations Open access
Semantic Scholar
Integrin clustering as a result of local membrane deformations and local signaling feedbacks
F. Felizzi, D. Iber
20144 citations
Semantic Scholar
Are Large Vision Language Models Truly Grounded in Medical Images? Evidence from Italian Clinical Visual Question Answering
F. Felizzi, Olivia Riccomi, Michele Ferramola, F. Causio +11 more
2025arXiv.org3 citations
Semantic Scholar
The Amblyopia Quality of Life (AmbQoL): Development and Content Validation of a Novel Health-Related Quality of Life Instrument for Use in Adult and Pediatric Amblyopia Populations
Ann L. Webber, S. Randhawa, F. Felizzi, M. Soós +6 more
2023Ophthalmology and Therapy3 citations Open access
Semantic Scholar
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
S. Spencer, G. Guzauskas, F. Felizzi, A. Launonen +3 more
2021Journal of Managed Care & Specialty Pharmacy3 citations Open access
Semantic Scholar
Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study
N. Paracha, F. Felizzi
20173 citations Open access
Semantic Scholar
Network-of-queues approach to B-cell-receptor affinity discrimination.
F. Felizzi, F. Comoglio
2012Physical review. E, Statistical, nonlinear, and soft matter physics3 citations
Semantic Scholar
POSC345 Qualitative Literature and Instrument Review to Develop a Clinical Outcome Assessment (COA) Measurement Strategy for Use in Amblyopia Studies
S. Randhawa, C. Cooper, N. Griffths, M. Soos +5 more
2022Value in Health2 citations Open access
Semantic Scholar
P1.01-052 Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC)
R. Bordoni, F. Ciardiello, J. von Pawel, D. Cortinovis +7 more
20172 citations Open access
Semantic Scholar
Artificial intelligence-based glaucoma screening in primary care: a cross-sectional study and economic viability analysis of an ongoing trial
Afonso Lima-Cabrita, Zahi Wehbi, Joana Pargana, Rafael Whitfield +21 more
2026The Lancet Primary Care1 citations Open access
Semantic Scholar
Economic impact of biomarker-based aging interventions on healthcare costs and individual value
F. Felizzi
2025Frontiers in Genetics1 citations Open access
Semantic Scholar
P4 Testing SimPy, a Library for Patient-Level Simulations in Python: An Application to Resource Management in Healthcare Systems
F. Felizzi
2023Value in Health1 citations
Semantic Scholar
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
F. Felizzi, A. Launonen, P. Thuresson
2022PharmacoEconomics - Open1 citations Open access
Semantic Scholar
EE405 A UK Cost-Minimisation Analysis of Brolucizumab Versus Aflibercept in Diabetic Macular Oedema (DMO)
S. Sydnor, M. Ibrahim, I. Singh, U. Vudumula +4 more
2022Value in Health1 citations Open access
Semantic Scholar
P48 Joint Modelling Measurable Target Lesions, EQ5D/Utility and Overall Survival: Do We Still Need Partitioned Survival Models?
F. Felizzi, A. Upton, N. Paracha
2022Value in Health1 citations Open access
Semantic Scholar
Semiparametric estimation of the cure fraction in population‐based cancer survival analysis
Ennan Gu, Jia-Jia Zhang, Wen-Bin Lu, Lian-Ming Wang +1 more
2020Statistics in Medicine1 citations
Semantic Scholar
Cost-Effectiveness of Polatuzumab Vedotin Plus Bendamustine-Rituximab for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States
K. Betts, F. Felizzi, I. Dieye, Jia Li +3 more
2020Blood1 citations Open access
Semantic Scholar
Microtubule tracking from stochastic optical reconstruction microscopy images
Juliane Liepe, F. Felizzi, Agata Pernuš, M. Hanulová
20121 citations
Semantic Scholar
A Monte Carlo study of ligand-dependent integrin signal initiation
F. Felizzi, D. Iber
20101 citations
Semantic Scholar
EuropeMedQA Study Protocol: A Multilingual, Multimodal Medical Examination Dataset for Language Model Evaluation
F. Causio, Vittorio De Vita, Olivia Riccomi, Michele Ferramola +16 more
2026arXiv.org0 citations
Semantic Scholar
Accelerometry-Derived Digital Biomarkers for Cardiometabolic Risk: A Population-Representative Tabular Benchmark with Uncertainty Quantification
F. Felizzi
2026arXiv.org0 citations
Semantic Scholar
A Framework for the Estimation of Quality-Adjusted Life-Years Using Joint Models of Longitudinal and Survival Data
M. Crowther, Alessandro Gasparini, Sara Ekberg, F. Felizzi +2 more
2026Medical decision making0 citations Open access
Semantic Scholar
CO247 The Relationship Between Surrogate Endpoints and Overall Survival in Myelofibrosis Clinical Trials: Results From a Targeted Literature Review
L. Linsell, Yuxian Chen, F. Felizzi, Santiago Moreno +5 more
2025Value in Health0 citations
Semantic Scholar
MSR149 Modeling Price Premiums of Oncology Drugs in Germany: A Cross-Validated Analysis Using XGBoost
F. Felizzi, V. Beykoz
2025Value in Health0 citations
Semantic Scholar
MSR73 A Framework for Estimating Quality Adjusted Life Years Using Joint Models of Longitudinal and Survival Data
M. Crowther, A. Gasparini, S. Ekberg, F. Felizzi +2 more
2024Value in Health0 citations Open access
Semantic Scholar
RWD130 Elacestrant vs Everolimus + Exemestane in Patients With ER+/HER2- ESR1-Mutated Advanced/Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy + CDK4/6 Inhibitor ≥12 Months: Combining Real-World and Clinical Trial Data
F. Felizzi, E. Fenu, S. Kloss, V. Laizet +2 more
2024Value in Health0 citations Open access
Semantic Scholar
EE519 Do We Need Three-State Decision Analytic Models in Metastatic Oncology? An Alternative Approach to Estimate Quality Adjusted Life Years (QALY)
F. Felizzi, N. Paracha
2023Value in Health0 citations
Semantic Scholar
POSC154 Cost-Effectiveness of Binocular Treatment for Amblyopia: A Markov Model Framework
T. Tai, J. Commane, K. Raunak, C. Bouchet +2 more
2022Value in Health0 citations Open access
Semantic Scholar
CO40 Vision-Related Quality of Life in Patients With Diabetic Macular Edema Treated With Brolucizumab 6 Mg vs Aflibercept 2 Mg in the Kestrel and Kite Studies
F. Felizzi, E. Bouillaud, V. Pagadala, F. Igwe +4 more
2022Value in Health0 citations Open access
Semantic Scholar
POSA74 Accounting for Population Heterogeneity Over-Time in Estimating Costs and Outcomes in Cohort-Based Health-Economic Evaluations
F. Felizzi, M. Manevy, D. Di Maio
2022Value in Health0 citations Open access
Semantic Scholar
Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
F. Felizzi, A. Launonen, P. Thuresson
2022PharmacoEconomics - Open0 citations Open access
Semantic Scholar
EE438 Assessing the Budget Impact of Automated Diabetic Retinopathy Screening: A Budget Impact Analysis in Germany
F. Felizzi, O. Ménage
2022Value in Health0 citations Open access
Semantic Scholar
POSC184 Targeted Literature Review Linking Wet Age-Related Macular Degeneration Real-World Evidence to Healthcare System Capacity and Spending
F. Felizzi, I. Singh, P. Le Nouveau, D. Pruce +1 more
2022Value in Health0 citations Open access
Semantic Scholar
MT27 Budget Impact of a Novel Digital Therapeutic for Amblyopia From a US Private Insurer Perspective
F. Felizzi, B. Reddy, J. Commane, P. O'Brien
2022Value in Health0 citations Open access
Semantic Scholar
PCN245 Opposing Duration of Treatment Effect Assumptions USED in the Health Technology Assessment of a Treatment for Rituximab-Refractory Follicular Lymphoma
K. Davé, T. Strunz-McKendry, F. Felizzi, A. Launonen +1 more
20200 citations Open access
Semantic Scholar
PCN279 PROBABILISTIC SENSITIVITY ANALYSIS: FAST WAYS TO MODEL THE COVARIANCE STRUCTURE
F. Felizzi
20200 citations Open access
Semantic Scholar
Abstract PO-58: Obinutuzumab plus chemotherapy is cost effective versus rituximab biosimilars plus chemotherapy for previously untreated follicular lymphoma patients
D. Veenstra, G. Guzauskas, S. Spencer, F. Felizzi +3 more
20200 citations
Semantic Scholar
Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
F. Castro, A. Surinach, A. Launonen, P. Thuresson +1 more
20200 citations Open access
Semantic Scholar
IBCL-199: Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma
D. Veenstra, G. Guzauskas, S. Spencer, F. Felizzi +3 more
2020Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Launonen×7
Invite
A. Launonen — researcher profile on SciRah
C. Bouchet×6
Invite
C. Bouchet — researcher profile on SciRah
A. Masaquel×5
Invite
A. Masaquel — researcher profile on SciRah
N. Paracha×4
Invite
N. Paracha — researcher profile on SciRah

×4

Invite

P. Thuresson — researcher profile on SciRah

J. von Pawel×3

Invite

J. von Pawel — researcher profile on SciRah

A. Rittmeyer×3

Invite

A. Rittmeyer — researcher profile on SciRah

D. Cortinovis×3

Invite

D. Cortinovis — researcher profile on SciRah

Invite

Pei He — researcher profile on SciRah

Invite

A. Sandler — researcher profile on SciRah

M. Ballinger×3

Invite

M. Ballinger — researcher profile on SciRah

Invite

D. Iber — researcher profile on SciRah